PMC:7381711 / 2984-3953 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T17","span":{"begin":0,"end":7},"obj":"Body_part"},{"id":"T18","span":{"begin":71,"end":86},"obj":"Body_part"},{"id":"T19","span":{"begin":88,"end":90},"obj":"Body_part"},{"id":"T20","span":{"begin":92,"end":110},"obj":"Body_part"},{"id":"T21","span":{"begin":133,"end":143},"obj":"Body_part"},{"id":"T22","span":{"begin":197,"end":199},"obj":"Body_part"},{"id":"T23","span":{"begin":200,"end":217},"obj":"Body_part"},{"id":"T24","span":{"begin":233,"end":240},"obj":"Body_part"},{"id":"T25","span":{"begin":332,"end":339},"obj":"Body_part"},{"id":"T26","span":{"begin":403,"end":411},"obj":"Body_part"},{"id":"T27","span":{"begin":457,"end":463},"obj":"Body_part"},{"id":"T28","span":{"begin":657,"end":659},"obj":"Body_part"},{"id":"T29","span":{"begin":762,"end":769},"obj":"Body_part"},{"id":"T30","span":{"begin":770,"end":777},"obj":"Body_part"},{"id":"T31","span":{"begin":930,"end":937},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma63011"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma63011"},{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma82764"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":133,"end":143},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000160"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"97","span":{"begin":501,"end":504},"obj":"Gene"},{"id":"98","span":{"begin":683,"end":686},"obj":"Gene"},{"id":"99","span":{"begin":722,"end":725},"obj":"Gene"},{"id":"100","span":{"begin":483,"end":499},"obj":"Gene"},{"id":"101","span":{"begin":0,"end":7},"obj":"Chemical"},{"id":"102","span":{"begin":71,"end":110},"obj":"Chemical"},{"id":"103","span":{"begin":197,"end":217},"obj":"Chemical"},{"id":"104","span":{"begin":233,"end":240},"obj":"Chemical"},{"id":"105","span":{"begin":332,"end":339},"obj":"Chemical"},{"id":"106","span":{"begin":457,"end":463},"obj":"Chemical"},{"id":"107","span":{"begin":618,"end":633},"obj":"Chemical"},{"id":"108","span":{"begin":762,"end":769},"obj":"Chemical"},{"id":"109","span":{"begin":930,"end":937},"obj":"Chemical"}],"attributes":[{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Gene:462"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Gene:462"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Gene:462"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"Gene:462"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:D006493"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"MESH:D006493"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D006493"},{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"MESH:D012694"},{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"MESH:D006493"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"MESH:D006493"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":11,"end":12},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":133,"end":143},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T10","span":{"begin":133,"end":143},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"},{"id":"T11","span":{"begin":538,"end":546},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T12","span":{"begin":567,"end":575},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T13","span":{"begin":608,"end":609},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T14","span":{"begin":818,"end":821},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

LitCovid-PD-CHEBI

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":524,"end":546},"obj":"http://purl.obolibrary.org/obo/GO_0050819"},{"id":"T2","span":{"begin":553,"end":575},"obj":"http://purl.obolibrary.org/obo/GO_0050819"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":0,"end":157},"obj":"Sentence"},{"id":"T23","span":{"begin":158,"end":312},"obj":"Sentence"},{"id":"T24","span":{"begin":313,"end":547},"obj":"Sentence"},{"id":"T25","span":{"begin":548,"end":714},"obj":"Sentence"},{"id":"T26","span":{"begin":715,"end":969},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

LitCovid-PD-GlycoEpitope

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T1","span":{"begin":71,"end":86},"obj":"GlycoEpitope"},{"id":"T2","span":{"begin":88,"end":90},"obj":"GlycoEpitope"},{"id":"T3","span":{"begin":197,"end":199},"obj":"GlycoEpitope"},{"id":"T4","span":{"begin":657,"end":659},"obj":"GlycoEpitope"}],"attributes":[{"id":"A1","pred":"glyco_epitope_db_id","subj":"T1","obj":"http://www.glycoepitope.jp/epitopes/EP0086"},{"id":"A2","pred":"glyco_epitope_db_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0086"},{"id":"A3","pred":"glyco_epitope_db_id","subj":"T3","obj":"http://www.glycoepitope.jp/epitopes/EP0086"},{"id":"A4","pred":"glyco_epitope_db_id","subj":"T4","obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

2_test

{"project":"2_test","denotations":[{"id":"32519894-28653068-2138150","span":{"begin":308,"end":310},"obj":"28653068"}],"text":"Heparin is a heterogeneous preparation of long, linear highly sulfated heparan sulfate (HS) glycosaminoglycans purified from porcine intestines (see Fig. 1). The sulfated nature of its constituent HS glycosaminoglycan chains confers heparin with the highest negative charge density of any known biomolecule (43). This charge allows heparin to strongly and selectively interact with an immense number of proteins, the most classic being its interaction with serine protease inhibitor antithrombin-III (AT3) that provides its anticoagulant activity. This anticoagulant activity is dependent on the presence of a precise pentasaccharide sequence within longer HS chains that allows for AT3 binding as shown in Fig. 1. Beyond AT3, hundreds of biologically relevant, heparin-protein interactions have been described, which has led to the recognition of an immense number of potential off-target (both positive and negative) effects of heparin of unknown clinical importance."}

PMC:7381711 / 2984-3953 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7381711 / 2984-3953 JSON TXT